In a patient with lobar pneumonia who was started on ceftriaxone and after one day shows a platelet count of 80 × 10⁹/L and hemoglobin of 11 g/dL, which medication should be discontinued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Stop Ceftriaxone Immediately

The medication that should be discontinued is C. Ceftriaxone, as this patient is exhibiting signs of drug-induced thrombocytopenia and possible hemolytic anemia, which are known adverse effects of cephalosporins, particularly ceftriaxone.

Clinical Reasoning

Why Ceftriaxone Must Be Stopped

The temporal relationship is critical here: the patient developed thrombocytopenia (platelets 80 × 10⁹/L) and low hemoglobin (11 g/dL) after one day of treatment initiation. This rapid onset strongly suggests:

  • Drug-induced immune thrombocytopenia (DITP): Ceftriaxone is one of the most common antibiotics causing this condition, with onset typically within 1-2 days in previously sensitized patients
  • Possible drug-induced hemolytic anemia: The combination of low hemoglobin with thrombocytopenia after ceftriaxone exposure raises concern for immune-mediated hemolysis

Why Not the Other Medications

  • Paracetamol (A): Does not cause acute thrombocytopenia or hemolytic anemia at therapeutic doses
  • Tramadol (B): Not associated with thrombocytopenia or significant hematologic adverse effects
  • Vancomycin (D): While it can rarely cause thrombocytopenia, this typically occurs after 7-14 days of therapy, not within 24 hours

Management Algorithm

Since the patient is clinically stable and improving from the pneumonia:

  1. Discontinue ceftriaxone immediately to prevent progression to severe thrombocytopenia or hemolysis
  2. Switch to alternative antibiotic coverage: Given the patient is improving, consider transitioning to a respiratory fluoroquinolone (levofloxacin, moxifloxacin) or azithromycin, which provide adequate coverage for community-acquired pneumonia without cross-reactivity 1
  3. Monitor platelet count and hemoglobin closely over the next 48-72 hours to confirm recovery after drug discontinuation

Critical Pitfall to Avoid

Do not continue ceftriaxone simply because the patient is clinically improving from pneumonia. Drug-induced thrombocytopenia can progress to life-threatening bleeding complications if the offending agent is not stopped promptly. The pneumonia can be adequately treated with alternative antibiotics that don't carry this risk.

References

Related Questions

In a patient with lobar pneumonia receiving IV ceftriaxone, paracetamol, and tramadol, who after one day is clinically stable but has thrombocytopenia (platelet count 70 ×10⁹/L) and hypoxemia (SpO₂ 88%), which medication should be stopped?
What antiemetic is recommended for a 6‑year‑old child and what is the appropriate dosing?
What is the appropriate ICD‑10‑CM code for a simple laceration on the right anterior lower leg after a dish injury, cleaned and dressed?
Should I obtain a respiratory viral panel for my cystic fibrosis patient who is experiencing a possible pulmonary flare with new fever and increased cough?
What first‑line medications should be recommended for adult patients in primary care for common conditions such as hypertension, hyperlipidemia, type 2 diabetes, bacterial sinusitis, community‑acquired pneumonia, uncomplicated urinary tract infection, anxiety/depression, mild pain, and intermittent asthma?
What is the recommended dexamethasone dosing regimen for altitude prophylaxis, including adjustments for hepatic impairment, renal insufficiency, COPD, and sulfonamide allergy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.